SCHEMBL9222018

SCHEMBL9222018

C/C=C(\C)CCC=C(C)COc1cc2cc3ccoc3cc2oc1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NDUFS8 O00217 2/20 0.43
COXFA4 O00483 2/20 0.43
NDUFAB1 O14561 2/20 0.43
NDUFA1 O15239 2/20 0.43
NDUFS4 O43181 2/20 0.43
NDUFB5 O43674 2/20 0.43
NDUFB3 O43676 2/20 0.43
NDUFC1 O43677 2/20 0.43
NDUFA2 O43678 2/20 0.43
NDUFS5 O43920 2/20 0.43
NDUFS7 O75251 2/20 0.43
NDUFS2 O75306 2/20 0.43
NDUFS6 O75380 2/20 0.43
NDUFB1 O75438 2/20 0.43
NDUFS3 O75489 2/20 0.43
NDUFB6 O95139 2/20 0.43
NDUFA3 O95167 2/20 0.43
NDUFB4 O95168 2/20 0.43
NDUFB8 O95169 2/20 0.43
NDUFB2 O95178 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10336303 0.74 HTT (0.48) CYP3A4KDM4EALDH1A1HSD17B10HPGD
SCHEMBL8897227 0.73 MAOA (0.50) CYP3A4KDM4EHSD17B10CYP2D6CYP2C9
SCHEMBL1713988 0.73 HTT (0.42) NDUFS8COXFA4NDUFAB1NDUFA1NDUFS4
SCHEMBL7754898 0.73 HTT (0.53) CYP3A4KDM4EALDH1A1HSD17B10HPGD
SCHEMBL1301705 0.71 CYP3A4 (0.62) CYP3A4TDP1KDM4EALDH1A1HSD17B10
SCHEMBL3447032 0.70 MAOA (0.47) CYP3A4KDM4EHSD17B10CYP2D6CYP2C9
SCHEMBL7877813 0.68 SIGMAR1 (0.49) CYP3A4TDP1KDM4EALDH1A1HSD17B10
SCHEMBL14152660 0.68 KCNA3 (0.51) CYP3A4KDM4EHSD17B10CYP2D6CYP2C9
SCHEMBL29419951 0.67 NDUFS8 (0.70) NDUFS8COXFA4NDUFAB1NDUFA1NDUFS4
SCHEMBL8936325 0.65 MAOA (0.56) ALOX15CYP3A4KDM4EALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114166961-B Method for measuring phenolic compounds in citrus juice product and pretreatment method thereof 西南大学 2022-11-22 CN claimed
JP-7025764-A None JP disclosed
US-20250032448-A1 COMPOUND FOR USE IN THE TREATMENT AND/OR PREVENTION OF PARASITIC MEDIATED DISEASES KOH, Hwee Ling (SG) 2025-01-30 US disclosed
US-12144797-B2 Compound for use in the treatment and/or prevention of parasitic mediated diseases KOH, Hwee Ling (SG) 2024-11-19 US disclosed
CN-111133087-A Cold treatment 西姆莱斯股份公司 2020-05-08 CN disclosed
EP-3389649-A1 COMPOUND FOR USE IN THE TREATMENT AND/OR PREVENTION OF PARASITIC MEDIATED DISEASES Leeward Pacific Pte Ltd (SG) 2018-10-24 EP disclosed
WO-2017155465-A1 COMPOUND FOR USE IN THE TREATMENT AND/OR PREVENTION OF PARASITIC MEDIATED DISEASES LEEWARD PACIFIC PTE LTD (SG) 2017-09-14 WO disclosed
JP-H0725764-A ANTIBACTERIAL AGENT POKKA CORP 1995-01-27 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12144797-B2 Compound for use in the treatment and/or prevention of parasitic mediated diseases ICMT, ALG3, PFN1 NDUFS8 1393/4885COXFA4 2294/4885NDUFAB1 2561/4885
US-20250032448-A1 COMPOUND FOR USE IN THE TREATMENT AND/OR PREVENTION OF PARASITIC MEDIATED DISEASES EPX, PKD2, MPO NDUFS8 1837/4885COXFA4 2828/4885NDUFAB1 2489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.